Bernat Olle

Bernat Olle is a prominent figure in the biotech industry, particularly in the field of microbiome therapeutics. He is the Chief Executive Officer, Co-founder, and member of the Board of Directors at Vedanta Biosciences, Inc., a company he has been leading since September 2015.1

Professional Background

Bernat Olle's career in the life sciences sector is extensive:

Vedanta Biosciences:

• Co-founded the company in February 2012
• Became CEO in September 2015
• Leads the development of oral therapies based on defined consortia of bacteria isolated from the human microbiome1

PureTech Health:

• Served as a Venture Partner from July 2007 to November 2016
• Held various positions, including Principal, Senior Associate, and Associate1

Follica, Inc.:

• Co-founder and Board member from June 2007 to January 2015
• Involved in developing novel treatments for androgenetic alopecia1

Education

Bernat Olle has a strong educational background in chemical engineering and business:

• PhD and MS in Chemical Engineering Practice from Massachusetts Institute of Technology (MIT)
• MBA from MIT Sloan School of Management
• B.Eng. in Chemical Engineering from Universitat Rovira i Virgili1

Achievements and Recognition

Throughout his career, Bernat Olle has received numerous accolades:

• Named Spanish Innovator of the Year under 35 by MIT Technology Review in 2013
• Recipient of the 2019 Immigrant Entrepreneur Award in Life Sciences
• Finalist for the Entrepreneur Of The Year® 2018 New England
• Named one of Boston Business Journal's 2018 40 Under 40 honorees
• Recognized as a Pharma Exec Emerging Pharma Leader in 20181

Bernat Olle's work at Vedanta Biosciences focuses on developing innovative microbiome-based therapeutics, with potential applications in areas such as C. difficile infection prevention, inflammatory bowel diseases, food allergies, and liver disease.1 His leadership has helped position Vedanta as a pioneer in the field of microbiome therapeutics, with a substantial patent portfolio and advanced capabilities in bacterial consortia drug development.